White Paper

Smart Equipment & Technology Selection: De-risks Your Monoclonal Antibody Scale-Up Process

Source: Avantor

By Timothy Korwan, Director – Technical Applications


Manufacturers are scaling up their monoclonal antibody (mAb) processes to meet a rising market demand. The time frame for mAbs, from research and development to commercialization, is thought to take a decade or more. Any delays during the clinical trial phase can cause significant additional costs. Innovations in raw materials, equipment and single-use technology continue to improve to help ;avoid obstacles and maximize efficiency.

Adopting a technology platform approach using a fluid handling system that can transition from development to your final production volume will ensure a smoother technology transfer and increased confidence in your process.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online